These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26488126)

  • 1. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate.
    Barco S; Whitney Cheung Y; Coppens M; Hutten BA; Meijers JC; Middeldorp S
    Br J Haematol; 2016 Jan; 172(2):255-61. PubMed ID: 26488126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
    Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
    J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
    Eerenberg ES; Kamphuisen PW; Sijpkens MK; Meijers JC; Buller HR; Levi M
    Circulation; 2011 Oct; 124(14):1573-9. PubMed ID: 21900088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
    Levy JH; Moore KT; Neal MD; Schneider D; Marcsisin VS; Ariyawansa J; Weitz JI
    J Thromb Haemost; 2018 Jan; 16(1):54-64. PubMed ID: 29106076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
    Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
    J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
    Zahir H; Brown KS; Vandell AG; Desai M; Maa JF; Dishy V; Lomeli B; Feussner A; Feng W; He L; Grosso MA; Lanz HJ; Antman EM
    Circulation; 2015 Jan; 131(1):82-90. PubMed ID: 25403645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
    Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
    Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
    Marlu R; Hodaj E; Paris A; Albaladejo P; Cracowski JL; Pernod G
    Thromb Haemost; 2012 Aug; 108(2):217-24. PubMed ID: 22627883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban.
    Dinkelaar J; Molenaar PJ; Ninivaggi M; de Laat B; Brinkman HJ; Leyte A
    J Thromb Haemost; 2013 Jun; 11(6):1111-8. PubMed ID: 23578206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
    Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
    Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban.
    Brown KS; Wickremasingha P; Parasrampuria DA; Weiss D; Kochan J; Dishy V; He L; Shi M
    Thromb Res; 2015 Oct; 136(4):825-31. PubMed ID: 26298619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers.
    Levi M; Moore KT; Castillejos CF; Kubitza D; Berkowitz SD; Goldhaber SZ; Raghoebar M; Patel MR; Weitz JI; Levy JH
    J Thromb Haemost; 2014 Sep; 12(9):1428-36. PubMed ID: 24811969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
    Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
    Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced Requirement for Prothrombin Complex Concentrate for the Restoration of Thrombin Generation in Plasma From Liver Transplant Recipients.
    Abuelkasem E; Hasan S; Mazzeffi MA; Planinsic RM; Sakai T; Tanaka KA
    Anesth Analg; 2017 Aug; 125(2):609-615. PubMed ID: 28537975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable outcome of rivaroxaban-associated intracerebral hemorrhage reversed by 4-factor prothrombin complex concentrate: impact on thrombin generation.
    Kauffmann S; Chabanne R; Coste A; Longeras F; Sinegre T; Schmidt J; Samama CM; Constantin JM; Lebreton A
    A A Case Rep; 2015 Jun; 4(11):151-4. PubMed ID: 26035221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study.
    Körber MK; Langer E; Ziemer S; Perzborn E; Gericke C; Heymann Cv
    Clin Appl Thromb Hemost; 2014 Oct; 20(7):735-40. PubMed ID: 23832064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation.
    Yasaka M; Sakata T; Naritomi H; Minematsu K
    Thromb Res; 2005; 115(6):455-9. PubMed ID: 15792675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.
    Perzborn E; Gruber A; Tinel H; Marzec UM; Buetehorn U; Buchmueller A; Heitmeier S; Laux V
    Thromb Haemost; 2013 Jul; 110(1):162-72. PubMed ID: 23636219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.